These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 16483866)

  • 1. Management of overactive bladder and urge urinary incontinence in the elderly patient.
    Erdem N; Chu FM
    Am J Med; 2006 Mar; 119(3 Suppl 1):29-36. PubMed ID: 16483866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?
    MacDiarmid SA
    BJU Int; 2007 Jun; 99 Suppl 3():8-12. PubMed ID: 17488367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The causes and consequences of overactive bladder.
    Miller J; Hoffman E
    J Womens Health (Larchmt); 2006 Apr; 15(3):251-60. PubMed ID: 16620184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic management of overactive bladder: practical options for the primary care physician.
    Staskin DR; MacDiarmid SA
    Am J Med; 2006 Mar; 119(3 Suppl 1):24-8. PubMed ID: 16483865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overactive bladder--a practical approach to evaluation and management.
    Madersbacher H
    J Med Liban; 2004; 52(4):220-6. PubMed ID: 16432986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer agents for the management of overactive bladder.
    Epstein BJ; Gums JG; Molina E
    Am Fam Physician; 2006 Dec; 74(12):2061-8. PubMed ID: 17186712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overactive bladder in the elderly: a guide to pharmacological management.
    Staskin DR
    Drugs Aging; 2005; 22(12):1013-28. PubMed ID: 16363885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overactive bladder: treatment options for the aging woman.
    Park SH; Davila GW
    Int J Fertil Womens Med; 2005; 50(1):37-44. PubMed ID: 15971720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of the Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study.
    Urinary Incontinence Treatment Network (UITN)
    Contemp Clin Trials; 2007 Jan; 28(1):48-58. PubMed ID: 16919506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.
    Ko Y; Malone DC; Armstrong EP
    Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary incontinence in the elderly population.
    Loh KY; Sivalingam N
    Med J Malaysia; 2006 Oct; 61(4):506-10; quiz 511. PubMed ID: 17243536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology of overactive bladder.
    Chu FM; Dmochowski R
    Am J Med; 2006 Mar; 119(3 Suppl 1):3-8. PubMed ID: 16483862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.